

Changes: May 2012

2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

[ISBN 978-1-61669-043-4, AHA Product Number 90-1040]

Page	Location	Original	Change
S708	Third paragraph under “Biphasic Waveform Defibrillators,” line 8	Therefore, for biphasic defibrillators, providers should use the manufacturer’s recommended energy dose (120 to 200 J) (Class I, LOE B).	Therefore, for biphasic defibrillators, providers should use the manufacturer’s recommended energy dose (eg, initial dose of 120 to 200 J) (Class I, LOE B).
S736	ACLS Cardiac Arrest Algorithm, in gray box, under “Shock Energy,” “Biphasic” bullet	Manufacturer recommendation (120-200 J); if unknown, use maximum available.	Manufacturer recommendation (eg, initial dose of 120-200 J); if unknown, use maximum available.
S737	ACLS Cardiac Arrest Circular Algorithm, in gray box, under “Shock Energy,” “Biphasic” bullet	Manufacturer recommendation (120-200 J); if unknown, use maximum available.	Manufacturer recommendation (eg, initial dose of 120-200 J); if unknown, use maximum available.
S738	Left column, first sentence under “Waveform and Energy”	If a biphasic defibrillator is available, providers should use the manufacturer’s recommended energy dose (120 to 200 J) for terminating VF (Class I, LOE B).	If a biphasic defibrillator is available, providers should use the manufacturer’s recommended energy dose (eg, initial dose of 120 to 200 J) for terminating VF (Class I, LOE B).
S774	Right column, last paragraph, line 5	Norepinephrine (levarterenol) and other catecholamines that activate β -adrenergic receptors	Norepinephrine (levarterenol) and other catecholamines that activate α -adrenergic receptors
S789	Figure 2, fourth line under the box for Step 2	Significant closed head/facial trauma within the previous 3 weeks	Significant closed head/facial trauma within the previous 3 months
S789	Under Figure 2	{Footnote added for Figure 2}	*Contraindications for fibrinolytic use in STEMI are viewed as advisory for clinical decision making and may not be all-inclusive or definitive. These contraindications are consistent with the 2004 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction.
S791	Right column, top of page, item 1 in numbered list, line 10	J-point elevation 0.15 mV (2.5 mm) in leads V2 and V3	J-point elevation 0.15 mV (1.5 mm) in leads V2 and V3

Page	Location	Original	Change
S831	Right column, line 7 in the first paragraph under “Troubleshooting After Intubation”	time (eg, adult inspiratory flow rate 80 to 100 mL/min)	time (eg, adult inspiratory flow rate 80 to 100 L/min)
S842	Left column, first full paragraph, line 12	Sustained infusions of concentrated dextrose solutions (<10%) require central venous access.	Sustained infusions of concentrated dextrose solutions (>10%) require central venous access.
S910	Figure. Newborn Resuscitation Algorithm, near the bottom of the algorithm	{The curved arrow between the eighth and the ninth boxes in the center column with the word “No” beside it}	{The curved arrow was replaced with a bidirectional arrow between the ninth box (“HR below 60?”) and the blue box on its left (“Take ventilation corrective steps/Intubate if no chest rise!”). The “No” that appeared next to the curved arrow was deleted.}
S935	In the Table, 10th member organization in the list	American Safety & Health Institute (ASHI) (Observer)	American Safety & Health Institute (ASHI)
S935	In the Table, 21st member organization in the list	Medic First Aid International (Observer)	Medic First Aid International
S938	Right column, second paragraph under “Snakebites,” line 4	entire length of the bitten extremity is an effective and safe way to slow the dissemination of venom	entire length of the bitten extremity is a reasonable way to slow the dissemination of venom
S938	Right column, second paragraph under “Snakebites,” line 10	benefit victims bitten by snakes producing neurotoxic venom, but the effectiveness	benefit victims bitten by snakes producing neurotoxic venom, ¹⁴⁰ but the effectiveness
S938	Right column, second paragraph under “Snakebites,” line 13	snakes. ^{140,141} The challenge is to find a way to teach the	snakes in an animal model. ¹⁴¹ This treatment requires further study to prove its efficacy in humans. The challenge is to find a way to teach the